Received Apr 30, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | FY293 | — |
Inappropriate dosing interval; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a elderly patient who received DTPa (Reduced antigen) (Boostrix) (batch number FY293, expiry date 23-JUN-2028) for prophylaxis. Previously administered products included Boostrix (1st dose received in 2015) and Boostrix (2nd dose received in 2025). On an unknown date, the patient received the 3rd dose of Boostrix. On an unknown date, an unknown time after receiving Boostrix, the patient experienced drug dose administration interval too short (Verbatim: Inappropriate dosing interval). The outcome of the drug dose administration interval too short was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 22-APR-2026 The patient recently received one dose of Boostrix in 2026, and after receiving this dose, the pharmacy manager became aware that the previous dose had been administered in 2025. The patient has received three doses of Boostrix: 2015, 2025, and 2026. The reporter did not have the exact date of administration.